Issue 5, 2006

Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

Abstract

We present the design, synthesis, and biological activity of three classes of tryptamine derivatives, which are non-planar analogues of the toxic anti-cancer agent fascaplysin. We show these compounds to be selective inhibitors of CDK4 over CDK2, the most active compound 9q has an IC50 for the inhibition of CDK4 of 6 µM.

Graphical abstract: Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

Article information

Article type
Paper
Submitted
19 Dec 2005
Accepted
12 Jan 2006
First published
01 Feb 2006

Org. Biomol. Chem., 2006,4, 787-801

Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin

C. Aubry, A. J. Wilson, P. R. Jenkins, S. Mahale, B. Chaudhuri, J. Maréchal and M. J. Sutcliffe, Org. Biomol. Chem., 2006, 4, 787 DOI: 10.1039/B518019H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements